-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
MaxCyte (NASDAQ:MXCT) Shares Up 5.8%
MaxCyte (NASDAQ:MXCT) Shares Up 5.8%
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating)'s stock price shot up 5.8% on Tuesday . The stock traded as high as $6.05 and last traded at $6.03. 4,183 shares were traded during mid-day trading, a decline of 99% from the average session volume of 580,017 shares. The stock had previously closed at $5.70.
Analyst Ratings Changes
Separately, BTIG Research lifted their price objective on shares of MaxCyte from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Sunday, August 14th.
Get MaxCyte alerts:MaxCyte Stock Performance
The firm has a market cap of $621.33 million, a price-to-earnings ratio of -30.50 and a beta of 1.17. The stock's 50 day simple moving average is $5.60.
Insider Buying and Selling at MaxCyte
In other MaxCyte news, major shareholder Casdin Partners Master Fund, L sold 3,235,548 shares of the business's stock in a transaction on Friday, July 1st. The shares were sold at an average price of $4.30, for a total transaction of $13,912,856.40. Following the completion of the sale, the insider now owns 10,735,786 shares in the company, valued at approximately $46,163,879.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.11% of the stock is currently owned by company insiders.Institutional Trading of MaxCyte
Institutional investors have recently made changes to their positions in the company. Quantbot Technologies LP bought a new stake in shares of MaxCyte in the 2nd quarter worth $27,000. Freemont Management S.A. purchased a new stake in MaxCyte during the first quarter valued at about $68,000. Nkcfo LLC purchased a new stake in MaxCyte during the first quarter valued at about $91,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in MaxCyte during the second quarter valued at about $76,000. Finally, PDT Partners LLC purchased a new stake in MaxCyte during the second quarter valued at about $76,000. Institutional investors own 66.40% of the company's stock.
MaxCyte Company Profile
(Get Rating)
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Further Reading
- Get a free copy of the StockNews.com research report on MaxCyte (MXCT)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- General Mills: Superior Returns With Less Volatility
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating)'s stock price shot up 5.8% on Tuesday . The stock traded as high as $6.05 and last traded at $6.03. 4,183 shares were traded during mid-day trading, a decline of 99% from the average session volume of 580,017 shares. The stock had previously closed at $5.70.
納斯達克股票代碼:MXCT-GET Rating)週二股價飆升5.8%,最高報6.05美元,尾盤報6.03美元。午盤成交量為4,183股,較580,017股的平均成交量下降99%。該股此前收盤報5.7美元。
Analyst Ratings Changes
分析師評級發生變化
Separately, BTIG Research lifted their price objective on shares of MaxCyte from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Sunday, August 14th.
另外,BTIG Research在8月14日(星期日)的一份研究報告中將MaxCyte的股票目標價從10.00美元上調至11.00美元,並給予該公司“買入”評級。
MaxCyte Stock Performance
Maxcell股票表現
The firm has a market cap of $621.33 million, a price-to-earnings ratio of -30.50 and a beta of 1.17. The stock's 50 day simple moving average is $5.60.
該公司市值為6.2133億美元,市盈率為-30.50倍,貝塔係數為1.17。該股的50日簡單移動均線切入位為5.60美元。
Insider Buying and Selling at MaxCyte
MaxCyte的內幕買賣
Institutional Trading of MaxCyte
MaxCyte的機構交易
Institutional investors have recently made changes to their positions in the company. Quantbot Technologies LP bought a new stake in shares of MaxCyte in the 2nd quarter worth $27,000. Freemont Management S.A. purchased a new stake in MaxCyte during the first quarter valued at about $68,000. Nkcfo LLC purchased a new stake in MaxCyte during the first quarter valued at about $91,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in MaxCyte during the second quarter valued at about $76,000. Finally, PDT Partners LLC purchased a new stake in MaxCyte during the second quarter valued at about $76,000. Institutional investors own 66.40% of the company's stock.
機構投資者最近對他們在該公司的頭寸進行了調整。Quantbot Technologies LP在第二季度購買了價值2.7萬美元的MaxCyte新股。Freemont Management S.A.在第一季度購買了MaxCyte的新股份,價值約6.8萬美元。Nkcfo LLC在第一季度購買了MaxCyte的新股份,價值約91,000美元。Zurcher Kantonalbank蘇黎世廣東銀行在第二季度購買了MaxCyte的新股份,價值約7.6萬美元。最後,PDT Partners LLC在第二季度購買了MaxCyte的新股份,價值約76,000美元。機構投資者持有該公司66.40%的股份。
MaxCyte Company Profile
Maxcell公司簡介
(Get Rating)
(獲取評級)
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Maxcell,Inc.是一家全球生命科學公司,致力於下一代細胞療法的發現、開發和商業化。其產品包括:Expert ATx,一種用於中小規模轉基因的靜態電穿孔儀器;Expert STx,一種用於蛋白質生產和藥物開發的流動電穿孔設備,以及用於基於細胞分析的治療靶點的表達;Expert GTx,一種用於治療應用中大規模轉基因的流動電穿孔設備;以及Expert VLx,用於超大規模細胞工程。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on MaxCyte (MXCT)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- General Mills: Superior Returns With Less Volatility
- 免費獲取StockNews.com關於MaxCyte的研究報告(MXCT)
- 對塔吉特來説,最糟糕的時期可能已經過去,但這隻股票買起來安全嗎?
- 這些液態天然氣股票準備好上行了嗎?
- 內部人士正在買入的兩隻有趣的股票
- 諾華在避險市場中仍是一隻冒險的股票
- 通用磨坊:波動性更小、回報更高
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
接收MaxCyte日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對MaxCyte和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧